• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Intrinsic capacity and its associations with incident dependence and mortality in 10/66 Dementia Research Group studies in Latin America, India, and China: A population-based cohort study
ConclusionsIn this study we observed a high prevalence of DICs, particularly in older age groups. Those affected had substantially increased risks of dependence and death. Most needs for care arose in those with DIC yet to become frail. Our findings provide some support for the strategy of optimising intrinsic capacity in pursuit of healthy ageing. Implementation at scale requires community-based screening and assessment, and a stepped-care intervention approach, with redefined roles for community healthcare workers and efforts to engage, train, and support them in these tasks. ICOPE might be usefully integrated into commu...
Source: PLoS Medicine - September 14, 2021 Category: Internal Medicine Authors: Martin J. Prince Source Type: research

Sex Differences in the Relationship Between Arterial Stiffness and Cognitive Function in Older Adults
Currently, dementia is a public health priority. The World Health Organization estimates 50 million people worldwide have dementia and every year there are nearly 10 million new cases.1 Dementia is a major cause of disability and dependency among older adults.1 As such, a better understanding of the mechanisms underlying cognitive decline will aid in developing targeted therapies for treatment and prevention.
Source: Journal of Stroke and Cerebrovascular Diseases - October 26, 2021 Category: Neurology Authors: Elizabeth Dao, Cindy K. Barha, Mij Santos, Madison Welch, Teresa Liu-Ambrose Source Type: research

Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Media News - July 24, 2023 Category: Pharmaceuticals Source Type: news

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13